Vebreltinib DR is under clinical development by Apollomics and currently in Phase II for Non-Small Cell Lung Cancer.

Vebreltinib DR is under clinical development by Apollomics and currently in Phase II for Head And Neck Cancer.

SARS-CoV-2, the virus behind the Covid-19 pandemic, remains in the skull and meninges for years after infection, leading to a long-lasting effect on the brain, according to a major German study.

One obstacle in developing effective treatments for patients with leptomeningeal disease has been the lack of reliable models to study the disease. However, a recent study has addressed this challenge ...